What is Betahistine Market?
Betahistine is a medicine that is used to treat the symptoms of Ménière's disease. Betahistine can be taken by adults aged 18 years and over and is not prescribed for children. Ménière's disease is a condition of the inner ear. It is normally causes attacks of dizziness with a spinning sensation which is vertigo, hearing loss and noises in the ear (tinnitus). The attacks can vary in severity, and in how often they occur. It is thought that a build-up of fluid in the inner ear causes the symptoms. The medicine holds 50 mg lactose monohydrate for 8 mg strength and 100 mg lactose monohydrate for 16 mg strength. Patients with rare hereditary irregularities of galactose tolerance, individuals with Lapp lactase deficiency or glucose-galactose malabsorption should not use this medication. The oral betahistine is approved for the treatment of Ménière’s disease and vestibular vertigo in more than 80 countries globally. However, In United States betahistine has not been approved for marketing for the past few decades.
The market study is being classified by Type (8mg, 16mg and 24mg), by Application (Vertigo, Tinnitus and Nausea) and major geographies with country level break-up.
Auris Medical Holding AG (Switzerland), TOWA PHARMACEUTICAL CO., LTD (Japan), Ciclum Farma Unipessoal (Portugal), EA Pharma Co., Ltd. (Japan), Nichi-Iko Pharmaceutical (Japan), DOC Generici (Italy), Takeda Pharmaceutical Company Limited (Japan), Orion Corporation (Finland), HENNIG ARZNEIMITTEL GmbH & Co. KG (Germany), Disphar International B.V. (Netherlands) and Mylan (United States) are some of the key players profiled in the study.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that Asian Players will contribute to the maximum growth of Global Betahistine market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Betahistine market by Type, Application and Region.
On the basis of geography, the market of Betahistine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Rise in Geriatric Population, Environmental Pollution, Noise Pollution
- Increase in the Changing In Lifestyle
- High Prevalence of Meniere’s Disease
- Increasing Awareness of This Disorder Is another Important Factor for the Market Growth
- Lack of Any Approved Drug or Treatment Option Is Restricting the Market Growth
- Rising Investment in the Research & Development for the Treatments for Meniere’s Disease
- Government Initiative to Increase Awareness Is Elevating the Market Growth
- Low Healthcare Expenditure in Developing Regions Also Acts As a Market Challenge
- Can Cause Unwanted Side-Effects Although Not Everyone Experiences Them
Key Target AudienceManufacturers of Betahistine, Suppliers of Betahistine, Wholesalers, Distributors and Retailers of Betahistine, Pharmaceutical Industry, Regulatory Bodies and Governmental bodies
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase